+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

Oncoimmunology 4(7): E1016709

Fractionated radiation therapy (RT) leads to adaptive changes in the tumor microenvironment that may limit the generation of an antitumor immune response. We demonstrated that fractionated RT led to increased tumor cell expression of programmed cell death ligand 1 (PD-L1) in response to CD8+ T cell production of interferon gamma. Our data reveal that the efficacy of fractionated RT can be significantly improved through the generation of durable systemic immune responses when combined with concurrent, but not sequential, blockade of the PD-1/PD-L1 pathway.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 059040232

Download citation: RISBibTeXText

PMID: 26140246

DOI: 10.1080/2162402x.2015.1016709

Related references

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology 7(3): E1395996, 2018

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clinical Cancer Research 23(18): 5514-5526, 2017

Changes in tumor cell response due to prolonged dose delivery times in fractionated radiation therapy. International Journal of Radiation Oncology, Biology, Physics 63(3): 892-900, 2005

Thymus involvement in immune system adaptive response to fractionated low-level gamma-radiation. Radiatsionnaya Biologiya Radioekologiya 34(4-5): 474-481, 1994

Interactions between antitumor drugs and radiation in mammalian tumor cell lines: differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro. Nci Monographs 1988(6): 177-181, 1988

Which Lung Tumors Shrink During Fractionated Radiation and How Does This Influence Outcome?: Appropriately Selecting Tumor and Treatment Characteristics for Adaptive Radiation Therapy Protocols. International Journal of Radiation Oncology*biology*physics 90(1): S641-S642, 2014

Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. Oncoimmunology 3(12): E954868, 2015

Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma. Cancer Biology & Therapy 2018: 1-14, 2018

Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Research 72(17): 4294-4299, 2012

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy. Oncoimmunology 8(1): E1513440, 2018

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. Oncoimmunology 5(6): E1145333, 2016

Effect of fractionated radiation therapy and dihydroxyanthraquinone on the response of a rat solid tumor. International Journal of Radiation Oncology*Biology*Physics 10(9): 1803-0, 1984

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery 6(8): 827-837, 2017

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Molecular Cancer Therapeutics 5(7): 1733-1743, 2006

Metabolic Tumor Volume Change During Radiation Therapy and Late-Course Adaptive Radiation Therapy in Patients With Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*biology*physics 90(1): S634-S635, 2014